Skip to main content

ORIGINAL RESEARCH article

Front. Oncol., 08 February 2021
Sec. Gastrointestinal Cancers
Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.589241

RETRACTED: ECT2 Increases the stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer

Retracted

A retraction of this article was approved in:

  1. Retraction: ECT2 Increases the Stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer

    1. Read retraction
Junxiong Wang,,Junxiong Wang1,2,3Shuo YangShuo Yang4Li Min,,Li Min1,2,3Shengtao Zhu,,Shengtao Zhu1,2,3Shuilong Guo,,Shuilong Guo1,2,3Shutian Zhang,,*Shutian Zhang1,2,3*
  • 1Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
  • 2Beijing Key Laboratory for Precancerous Lesion of Digestive Diseases, Beijing, China
  • 3National Clinical Research Centre for Digestive Diseases, Beijing, China
  • 4Department of Laboratory Medicine, Peking University Third Hospital, Beijing, China

This article has been retracted. Please follow the link to the full retraction notice for details.

Citation: Wang J, Yang S, Min L, Zhu S, Guo S and Zhang S (2021) ECT2 Increases the stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer. Front. Oncol. 10:589241. doi: 10.3389/fonc.2020.589241

Received: 30 July 2020; Accepted: 17 December 2020;
Published: 08 February 2021; Retracted: 19 July 2021.

Edited by:

Linhui Liang, Fudan University, China

Reviewed by:

Bingqing Huang, Chinese Academy of Medical Sciences and Peking Union Medical College, China
Wei Zhao, Chengdu Medical College, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.